430 related articles for article (PubMed ID: 15034864)
41. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
42. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.
Kao J; Pollack JR
Genes Chromosomes Cancer; 2006 Aug; 45(8):761-9. PubMed ID: 16708353
[TBL] [Abstract][Full Text] [Related]
43. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
44. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Kauraniemi P; Kallioniemi A
Endocr Relat Cancer; 2006 Mar; 13(1):39-49. PubMed ID: 16601278
[TBL] [Abstract][Full Text] [Related]
45. Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.
Zaczek A; Markiewicz A; Jaśkiewicz J; Pieńkowski T; Rhone P; Jassem J; Wełnicka-Jaśkiewicz M
Clin Biochem; 2010 Jul; 43(10-11):891-8. PubMed ID: 20441774
[TBL] [Abstract][Full Text] [Related]
46. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome.
Skotheim RI; Kallioniemi A; Bjerkhagen B; Mertens F; Brekke HR; Monni O; Mousses S; Mandahl N; Soeter G; Nesland JM; Smeland S; Kallioniemi OP; Lothe RA
J Clin Oncol; 2003 Dec; 21(24):4586-91. PubMed ID: 14673046
[TBL] [Abstract][Full Text] [Related]
47. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer.
Arriola E; Moreno A; Varela M; Serra JM; Falo C; Benito E; Escobedo AP
Eur J Cancer; 2006 Nov; 42(17):2954-60. PubMed ID: 16935488
[TBL] [Abstract][Full Text] [Related]
48. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.
Mezzelani A; Alasio L; Bartoli C; Bonora MG; Pierotti MA; Rilke F; Pilotti S
Br J Cancer; 1999 May; 80(3-4):519-25. PubMed ID: 10408862
[TBL] [Abstract][Full Text] [Related]
49. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis.
Lan C; Liu JM; Liu TW; Hsu DH; Liang S; Chen JR; Peng JW
Am J Clin Pathol; 2005 Jul; 124(1):97-102. PubMed ID: 15923160
[TBL] [Abstract][Full Text] [Related]
50. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
Courjal F; Theillet C
Cancer Res; 1997 Oct; 57(19):4368-77. PubMed ID: 9331100
[TBL] [Abstract][Full Text] [Related]
51. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
García-Caballero T; Prieto O; Vázquez-Boquete A; Gude F; Viaño P; Otero M; Curiel T; Fernández-Rodríguez B; Parrado C; Fraga M; Antúnez JR
Breast Cancer Res Treat; 2014 Jan; 143(1):81-9. PubMed ID: 24292870
[TBL] [Abstract][Full Text] [Related]
52. Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.
Liu JM; Chen LT; Li AF; Wu CW; Lan C; Chung TR; Shiah HS; Lee KD; Liu TW; Peng JW
Jpn J Clin Oncol; 2004 Dec; 34(12):727-32. PubMed ID: 15640503
[TBL] [Abstract][Full Text] [Related]
53. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
Järvinen TA; Liu ET
Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
[TBL] [Abstract][Full Text] [Related]
54. DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas.
Bredel C; Lassmann S; Pollack IF; Knoth R; Hamilton RL; Volk B; Werner M; Bredel M
Int J Oncol; 2005 May; 26(5):1187-92. PubMed ID: 15809708
[TBL] [Abstract][Full Text] [Related]
55. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
Mrhalova M; Kodet R
Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
[TBL] [Abstract][Full Text] [Related]
56. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
Glynn RW; Miller N; Whelan MC; Kerin MJ
Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
[TBL] [Abstract][Full Text] [Related]
57. Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17.
Corzo C; Tusquets I; Suarez M; Fabregat X; Salido M; Solé F; Corominas JM; Serrano S
Cancer Genet Cytogenet; 2004 Oct; 154(1):89-90. PubMed ID: 15381381
[No Abstract] [Full Text] [Related]
58. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
Gennari A; Pronzato P
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
[TBL] [Abstract][Full Text] [Related]
59. Genetic alterations in ERBB2-amplified breast carcinomas.
Isola J; Chu L; DeVries S; Matsumura K; Chew K; Ljung BM; Waldman FM
Clin Cancer Res; 1999 Dec; 5(12):4140-5. PubMed ID: 10632352
[TBL] [Abstract][Full Text] [Related]
60. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]